Status:

RECRUITING

Evaluation of HEArt invoLvement in Patients With FABRY Disease

Lead Sponsor:

Wuerzburg University Hospital

Collaborating Sponsors:

Competence Network Heart Failure

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Conditions:

Rare Diseases

Fabry Disease

Eligibility:

All Genders

18+ years

Brief Summary

This study evaluates predictors for the incidence of arrhythmias and sudden cardiac death as well as terminal heart failure in patients with Fabry disease.

Detailed Description

Fabry disease is a rare disease and part of the group of lysosomal storage disorders. Natural history of Fabry disease has proven poor survival to ages \>50 years outlining the importance to evaluate ...

Eligibility Criteria

Inclusion

  • Fabry disease (genetically confirmed)
  • Signed informed consent
  • 18 years and older

Exclusion

  • No informed consent
  • Withdrawal of informed consent

Key Trial Info

Start Date :

January 1 2001

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

March 1 2032

Estimated Enrollment :

650 Patients enrolled

Trial Details

Trial ID

NCT03362164

Start Date

January 1 2001

End Date

March 1 2032

Last Update

July 7 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wuerzburg University Hospital

Würzburg, Bavaria, Germany, 97080

Evaluation of HEArt invoLvement in Patients With FABRY Disease | DecenTrialz